Aadi Bioscience Inc (AADI) - חוב להון עצמי

Aadi Bioscience (AADI) relies on external certified facilities in the US for its production cycle, which mitigates the risk of plant shutdowns. This price chart on GURU.Markets shows that the total debt-to-equity ratio is 0.01. The company is currently conducting its own development testing, limiting itself to only narrow partnerships. High FDA certification costs and patent protection create significant barriers to entry.

The use of strict SLAs with contract manufacturers allows Aadi Bioscience to minimize capital expenditures, which directly impacts the dynamics of the total debt-to-equity ratio. This indicator, calculated as the sum of all liabilities relative to shareholders' equity, determines the level of credit burden and the issuer's financial autonomy, where low values confirm the resilience of the business model and high investment attractiveness.